VIDEO: Understanding GLOBE and GUARD in most-favored-nation pricing with Tim Wright, Genesis Research Group

Most-favored-nation (MFN) pricing requires manufacturers to provide rebates when US drug prices exceed those in selected reference countries. The approach is intended to address the persistent gap between US drug prices and those in other developed markets. By linking US prices to international benchmarks, MFN pricing introduces significant uncertainty for manufacturers as policymakers consider multiple models and implementation pathways. Understanding how these policies are structured and how they may be applied in practice is critical for manufacturers seeking to anticipate pricing risk and plan accordingly.

Building on the earlier video in this series, where Tim Wright, Executive Vice President for Access and Pricing at Genesis Research Group, examined the MFN debate and its relationship with the GENEROUS Model and the Inflation Reduction Act, this video focuses on the newly introduced mandatory MFN models GLOBE (Global Benchmark for Efficient Drug Pricing) and GUARD (Guarding US Medicare Against Rising Drug Costs). Wright outlines what these models entail, how they interact with existing pricing initiatives, and what they could mean for global pricing strategies.

Speaker

Tim Wright
Executive Vice President, Access and Pricing, Genesis Research Group

Tim Wright leads the Access & Pricing division at Genesis Research Group. An economist and health economist, Tim has 30 years of experience in the biopharma sector, including 18 years in executive positions in strategic consulting firms and 12 years in global EU and UK roles in industry. In consulting, Tim has provided strategic leadership in over 1000 engagements with small biotechs to top-five pharma and across all therapy areas. Within the industry, Tim was responsible for global pricing and access strategy for two mega-brands and the CV, respiratory, infection and inflammation early asset portfolio at AstraZeneca. He is former Head of HEOR at Janssen Cilag UK, and brings experience from EU Pricing for Allergan and his time as a clinical scientist at Astra.

The views and opinions expressed in this feature are those of the interviewee and do not necessarily reflect the views or positions of Genesis Research Group and its affiliates. The information provided is for general information purposes only and should not be taken as professional advice.

The opinions expressed in this feature are those of the author and do not necessarily reflect the views of The Evidence Base® or Becaris Publishing Ltd.

Sponsorship for this Video was provided by Genesis Research Group.